General
As with any percutaneous vaccine, epinephrine (1:1000) should be available
for immediate use should an anaphylactoid reaction occur.
Any serious active infection including febrile illness is reason for delaying
use of the vaccine except when in the opinion of the physician, withholding
the vaccine entails a greater risk.
Caution and appropriate care should be exercised in administering the vaccine
to individuals with severely compromised cardiopulmonary status or to others
in whom a febrile or systemic reaction could pose a significant risk.
Instructions to Healthcare Provider
The healthcare provider should determine the current health status and previous
vaccination history of the vaccinee.
The healthcare provider should question the patient, parent or guardian about
reactions to a previous dose of RECOMBIVAX (hepatitis b vaccine (recombinant)) HB or other hepatitis B vaccines.
The healthcare provider must record in the patient's permanent record: the
manufacturer, lot number, date of administration, and the name and address of
the person administering the vaccine.
Injection of a blood vessel should be avoided.
Information for Vaccine Recipients and Parents/Guardians
The healthcare provider should provide the vaccine information required to
be given with each vaccination to the patient, parent or guardian.
The healthcare provider should inform the patient, parent or guardian of the
benefits and risks associated with vaccination, as well as the importance of
completing the immunization series. For risks associated with vaccination, see
WARNINGS, PRECAUTIONS, and ADVERSE
REACTIONS.
Patients, parents and guardians should be instructed to report any serious
adverse reactions to their healthcare provider, who in turn should report such
events to the U.S. Department of Health and Human Services through the Vaccine
Adverse Event Reporting System (VAERS), 1-800-822-7967.31 The healthcare
provider should inform the parent or guardian of the National Vaccine Injury
Compensation Program (NVICP), 1-800-338-2382.
Carcinogenesis, Mutagenesis, Impairment of Fertility
RECOMBIVAX (hepatitis b vaccine (recombinant)) HB has not been evaluated for its carcinogenic or mutagenic potential,
or its potential to impair fertility.
Pregnancy
Pregnancy Category C: Animal reproduction studies have not been
conducted with the vaccine. It is also not known whether the vaccine can cause
fetal harm when administered to a pregnant woman or can affect reproduction
capacity. The vaccine should be given to a pregnant woman only if clearly needed.
Nursing Mothers
It is not known whether the vaccine is excreted in human milk. Because many
drugs are excreted in human milk, caution should be exercised when the vaccine
is administered to a nursing woman.
Pediatric Use
RECOMBIVAX (hepatitis b vaccine (recombinant)) HB has been shown to be usually well-tolerated and highly immunogenic
in infants and children of all ages. Newborns also respond well; maternally
transferred antibodies do not interfere with the active immune response to the
vaccine. See DOSAGE AND ADMINISTRATION for recommended pediatric dosage
and for recommended dosage for infants born to HBsAg positive mothers.
The safety and effectiveness of RECOMBIVAX (hepatitis b vaccine (recombinant)) HB Dialysis Formulation in children
have not been established.
Geriatric Use
Clinical studies of RECOMBIVAX (hepatitis b vaccine (recombinant)) HB did not include sufficient numbers of subjects
aged 65 and over to determine whether they respond differently from younger
subjects. Other reports from the clinical literature indicate that hepatitis
B vaccines are less immunogenic in adults aged 65 years or older than in younger
individuals.32 No overall differences in safety were observed between
these subjects and younger subjects.
REFERENCES
10. Data on file at Merck Research Laboratories.
31. Vaccine Adverse Event Reporting System - United States.
MMWR 39(41): 730-733, October 19, 1990.
32. Zajac, B.A.; West, D.J.; McAleer, W.J.; Scolnick, E.M.:
Overview of Clinical Studies with Hepatitis B Vaccine Made by Recombinant DNA,
J. Infection, 13(Sup. A): 39-45, July 1986.
Last reviewed on RxList: 9/2/2008
This monograph has been modified to include the generic and brand name in many instances.